BACKGROUND: Gabapentin and pregabalin are widely used as antineuropathic pain drugs. Their use is also associated with the development of adverse drug reactions (ADRs), mainly neuropsychiatric. OBJECTIVE: The aim of this work was to study 'serious' and/or 'unexpected' adverse reactions associated with pregabalin and gabapentin. STUDY DESIGN: We studied ADRs reported to the French Pharmacovigilance System occurring between 1995 and 2009. MAIN OUTCOME MEASURE: For each ADR associated with gabapentin or pregabalin, we noted year, patient age and sex, type of adverse reaction, as well as the imputability score. Reporting rate of serious ADRs for gabapentin and pregabalin was estimated with regard to data of use (obtained from the French National Health Insurance Fund) using the defined daily dose. A global and descriptive analysis of the adverse reactions for each drug is presented. Secondly, details of deaths and ADRs with an imputability score of at least 'probable' or 'likely' were presented. RESULTS: Overall, 1333 cases were recorded (725 related to gabapentin, 608 related to pregabalin), mainly neuropsychiatric ADRs. Among the 22 deaths recorded, 8 were related to gabapentin in obstetrical situations. Other less well-documented ADRs were identified, such as hepatitis associated with gabapentin and haematological ADRs associated with pregabalin. CONCLUSION: This study confirmed the prevalence of neuropsychiatric ADRs associated with gabapentin or pregabalin. A high rate of death occurred with gabapentin in an obstetrical context. New adverse reactions have been noted, such as haematological or hepatic adverse reactions associated with pregabalin and gabapentin, respectively.
BACKGROUND:Gabapentin and pregabalin are widely used as antineuropathic pain drugs. Their use is also associated with the development of adverse drug reactions (ADRs), mainly neuropsychiatric. OBJECTIVE: The aim of this work was to study 'serious' and/or 'unexpected' adverse reactions associated with pregabalin and gabapentin. STUDY DESIGN: We studied ADRs reported to the French Pharmacovigilance System occurring between 1995 and 2009. MAIN OUTCOME MEASURE: For each ADR associated with gabapentin or pregabalin, we noted year, patient age and sex, type of adverse reaction, as well as the imputability score. Reporting rate of serious ADRs for gabapentin and pregabalin was estimated with regard to data of use (obtained from the French National Health Insurance Fund) using the defined daily dose. A global and descriptive analysis of the adverse reactions for each drug is presented. Secondly, details of deaths and ADRs with an imputability score of at least 'probable' or 'likely' were presented. RESULTS: Overall, 1333 cases were recorded (725 related to gabapentin, 608 related to pregabalin), mainly neuropsychiatric ADRs. Among the 22 deaths recorded, 8 were related to gabapentin in obstetrical situations. Other less well-documented ADRs were identified, such as hepatitis associated with gabapentin and haematological ADRs associated with pregabalin. CONCLUSION: This study confirmed the prevalence of neuropsychiatric ADRs associated with gabapentin or pregabalin. A high rate of death occurred with gabapentin in an obstetrical context. New adverse reactions have been noted, such as haematological or hepatic adverse reactions associated with pregabalin and gabapentin, respectively.
Authors: Martin Grosshans; Jochen Mutschler; Derik Hermann; Oliver Klein; Harald Dressing; Falk Kiefer; Karl Mann Journal: Am J Psychiatry Date: 2010-07 Impact factor: 18.112
Authors: J Morrow; A Russell; E Guthrie; L Parsons; I Robertson; R Waddell; B Irwin; R C McGivern; P J Morrison; J Craig Journal: J Neurol Neurosurg Psychiatry Date: 2005-09-12 Impact factor: 10.154
Authors: Robert W Hurley; Steven P Cohen; Kayode A Williams; Andrew J Rowlingson; Christopher L Wu Journal: Reg Anesth Pain Med Date: 2006 May-Jun Impact factor: 6.288
Authors: Janneke Jentink; Maria A Loane; Helen Dolk; Ingeborg Barisic; Ester Garne; Joan K Morris; Lolkje T W de Jong-van den Berg Journal: N Engl J Med Date: 2010-06-10 Impact factor: 91.245
Authors: Janneke Jentink; Helen Dolk; Maria A Loane; Joan K Morris; Diana Wellesley; Ester Garne; Lolkje de Jong-van den Berg Journal: BMJ Date: 2010-12-02
Authors: Chan Mi Park; Sharon K Inouye; Edward R Marcantonio; Eran Metzger; Brian T Bateman; Jessica J Lie; Su Been Lee; Raisa Levin; Dae Hyun Kim Journal: JAMA Intern Med Date: 2022-09-19 Impact factor: 44.409
Authors: Christine Sanderson; Stephen J Quinn; Meera Agar; Richard Chye; Katherine Clark; Matthew Doogue; Belinda Fazekas; Jessica Lee; Melanie R Lovell; Debra Rowett; Odette Spruyt; David C Currow Journal: BMJ Support Palliat Care Date: 2014-10-16 Impact factor: 3.568
Authors: Leticia Ortiz de Landaluce; Pere Carbonell; Carmen Asensio; Núria Escoda; Pilar López; Joan-Ramon Laporte Journal: Drug Saf Date: 2018-12 Impact factor: 5.606
Authors: Francois Pognan; J Andreas Mahl; Maria Papoutsi; David Ledieu; Marc Raccuglia; Diethilde Theil; Sarah B Voytek; Patrick J Devine; Katie Kubek-Luck; Natalie Claudio; Andre Cordier; Annabelle Heier; Carine Kolly; Andreas Hartmann; Salah-Dine Chibout; Page Bouchard; Christian Trendelenburg Journal: Arch Toxicol Date: 2018-03-19 Impact factor: 5.153